Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 8.01
The disclosure centers on the launch of a new nutritional products division representing a material expansion into energy drinks, nutritional products, and dietary supplements. This is a strategic business initiative that would affect a reasonable investor's assessment of the company's future direction and growth prospects, though the division remains in early-stage development with uncertain timelines and regulatory approvals. The telephone number correction is administrative and immaterial.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 8.01
Summit disclosed positive Phase III clinical trial results for its partner Akeso's HARMONi-GI1 study of ivonescimab in advanced biliary tract cancer, achieving statistically significant overall survival superiority versus durvalumab plus chemotherapy. This represents a material operational/clinical milestone for Summit's lead investigational asset (SMT112/ivonescimab), supporting its ongoing regulatory pathway and commercial potential, though the trial was sponsored and conducted by Akeso rather than Summit directly. The event is operational rather than a specific earnings release, regulatory approval, or M&A activity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-25
EX-99.1
Diana Shipping announces a time charter contract extension for the m/v Leto with Cargill International SA at US$18,000 per day (up from US$12,750 per day) for a period through September 2027–October 2027, expected to generate approximately US$6.34 million in gross revenue. This is a material operational and commercial event—a significant vessel employment contract renewal at improved rates—but does not fit the specific event-type categories (not M&A, not a financial obligation issuance, not a restructuring). It is a material contract milestone affecting the Company's revenue and fleet utilization.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 8.01
The filing discloses a business update on ROAMEO autonomous vehicle deployment progress, including current deployments, production targets (7 units by end of 2026, 50 by August 2027), and component procurement. This is an operational/strategic milestone disclosure rather than a financial event, earnings release, or governance matter. While the company emphasizes these are estimates subject to risks (including going-concern doubts mentioned in forward-looking statements), the core disclosure is a product deployment and production readiness update material to investors assessing the company's operational progress and commercialization trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-25
EX-99.1
This exhibit is a drilling results announcement from NexGen Energy's Patterson Corridor East (PCE) uranium exploration project. The disclosure reports significant expansion of high-grade mineralization (vertical extent increased 17% to 644 m), discovery of multiple stacked uranium veins with strong continuity, and the company's decision to add a fifth drill rig to accelerate development. While exploration results are not a discrete event type in the taxonomy, this represents a material operational/strategic milestone that would affect investor assessment of the company's long-term resource base and project advancement trajectory, particularly given the company's parallel construction of the Rook I Project.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 7.01
The disclosure reports an operational update on mining success at Stibnite Hill, Montana, including production metrics (42 truckloads, 576 tons of ore, 10% antimony content) and improved mining rates (three truckloads per day, over twice faster than 2025). This is a material operational milestone demonstrating progress on the Company's stated strategy to expand domestic antimony feedstock and reduce reliance on third-party ore, but it does not fit the specific categories of earnings release, M&A activity, workforce reduction, or other named event types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 8.01
Theravance disclosed results of the Phase 3 CYPRESS Study (0197) for ampreloxetine in nOH/MSA, which missed its primary endpoint (OHSA composite score at week 8 was not statistically significant). The company also disclosed post hoc analyses and FDA interactions, including a Type B meeting in May 2026 where the FDA indicated the existing data would not support approval but suggested an additional pivotal trial could offer a potential path forward, and a requested Type C meeting in July 2026 to align on future study design. This is a material clinical development milestone and regulatory setback for a key pipeline asset, disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-25
EX-99.1
This press release announces Phase 2 infill drill results from Fury's Eau Claire Gold Project, reporting assay results from 22 drill holes totalling 11,423 metres. The disclosure focuses on exploration progress—demonstrating "strong continuity of gold mineralization" and supporting "resource conversion objectives" toward pre-feasibility in 2027. While not a discrete operational event like a partnership or contract, the results are material to investors assessing the company's exploration advancement and project viability, particularly given Fury's stated focus on advancing Eau Claire toward development.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-25
EX-99.1
The press release announces that the U.S. FDA has granted Orphan Drug Designation to gamgertamig for treatment of pemphigus, a regulatory milestone for Lakefront's lead clinical-stage asset. This is a material operational/regulatory event that advances the company's development program and provides competitive advantages (orphan drug status), but it is not a discrete transaction (M&A), financial obligation (debt), capital event (dilution), or personnel change. The designation is a significant clinical and regulatory achievement that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-25
EX-99.1
This press release announces ParaZero's first DefendAir order from a U.S. federal security entity, marking the company's entry into the U.S. Counter-UAS market. The disclosure describes a material commercial milestone—a significant customer win in a new geographic market (U.S. federal government)—that reflects successful market penetration and validates the company's Counter-UAS strategy. While not a discrete M&A transaction, debt issuance, or earnings announcement, this represents a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's growth trajectory and market traction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-25
Item 7.01
Generate Biomedicines disclosed that draft clinical trial posters for its lead candidate GB-0895 were inadvertently made publicly available via the ERS website prior to the embargo expiration. The company proactively furnished the final posters as Exhibit 99.1 to ensure accurate disclosure of ongoing Phase 1 and Phase 3 trial data for asthma and COPD indications. This is a material operational/disclosure event involving clinical trial data for a development-stage biotech company, though the company's precautionary measure mitigates the severity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
The filing discloses a clinical development milestone: the first patient dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea. This represents material operational progress for a clinical-stage biopharmaceutical company, building on prior positive Phase 2 RePOSA results and FDA Fast Track designation. While not a specific named event type, this is clearly an operational/clinical milestone that would affect a reasonable investor's assessment of the company's drug development progress and timeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 7.01
The disclosure announces a technical collaboration between Electra (the SPAC target) and MinTech to integrate battery diagnostic equipment with AI-powered analytics for battery energy storage systems. This is a material operational/strategic partnership that advances Electra's core business capabilities and market positioning. While disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated M&A item, the collaboration represents a significant commercial relationship that would affect investor assessment of Electra's technology roadmap and competitive positioning ahead of the pending business combination.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-25
EX-99.1
This press release announces a $38.8 million commercial purchase order from Japanese client WOODMAN Inc. for NVIDIA B300 GPU-based server clusters, representing SuperX's first commercial collaboration with this customer and a significant expansion into Japan's AI infrastructure market. While the order is material in scale and strategic importance, it is fundamentally a large commercial contract/customer win rather than a discrete event fitting the specific taxonomy categories (not M&A, not a financial obligation like debt issuance, not a restructuring). This is best classified as an operational/strategic business event—a material contract and market expansion milestone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-25
Item 8.01
Adaptin Bio announced the opening of enrollment in a Phase 1 clinical trial for APTN-101, its proprietary BRiTE therapeutic for glioblastoma treatment. This represents a material operational and clinical development milestone—the transition from preclinical to first-in-human clinical testing—that would affect a reasonable investor's assessment of the company's pipeline progress and near-term value drivers. While not fitting a specific named event type, this is clearly an operational/strategic milestone in the company's drug development program.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-25
EX-99.1
This news release discloses results of advanced metallurgical test work on the Apollo deposit showing strong recovery rates (95% gold, 92% silver, 85% copper, 70% tungsten) and announces acceleration of the timeline to release a maiden mineral resource estimate in September 2026. The disclosure is primarily operational—reporting on exploration and development progress at the flagship Guayabales Project—rather than a discrete event like M&A, executive change, or financial results. It is material because metallurgical recovery rates and resource estimation timelines directly affect investor assessment of the project's development potential and value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-25
EX-99.1
First Mining has entered into a Project Agreement with Slate Falls Nation governing development of the Springpole Gold Project, a major gold resource in northwestern Ontario. The agreement establishes collaborative frameworks for environmental management, employment, training, business opportunities, and financial benefit-sharing with the First Nation. This is a material operational and strategic milestone for advancing one of Canada's largest gold projects, following the federal Environmental Assessment approval in June 2026, and does not fit a discrete event category (not M&A, not a financing, not a governance change) but is clearly a significant operational/partnership development affecting the project's path to development.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-25
The disclosure announces a 2-year time charter contract extension for the M/V Jonathan P at $26,000/day, expected to generate approximately $12.7 million EBITDA over the minimum contracted period and increase charter coverage through 2028. This is a material operational and commercial event for a shipping company—securing long-term vessel employment at profitable rates directly affects revenue and cash flow. While not a discrete M&A transaction, it is a significant commercial contract that a reasonable investor would consider material to assessing the company's operational performance and financial outlook.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 7.01
The disclosure announces two new build-to-suit development projects totaling $23 million in committed pipeline investment for Hobby Lobby and Academy Sports, with construction started in August 2026 and expected delivery in Q2 2027. This is a material operational/strategic business event involving property acquisitions and development activity central to BNL's REIT business model, but does not fit the specific categories of M&A activity (no acquisition of an existing company), debt issuance, or other named financial events. The event would affect a reasonable investor's assessment of the company's growth pipeline and capital deployment strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-25
Item 7.01
The disclosure centers on operational and strategic progress toward completing a planned acquisition of a 132-acre biomass power facility in East Texas, including engagement of MDM Group to market the site to data center operators and AI companies, engagement of a power-generation services provider for plant recommissioning, and status updates on acquisition financing and closing timeline. While acquisition-related, the filing emphasizes operational workstreams and commercialization efforts rather than announcing a completed or materially altered M&A transaction; the acquisition remains subject to financing and has not closed. This is best classified as operational_other—a material strategic business development and project advancement—rather than ma_activity, which typically signals entry into, completion, or material change to an M&A agreement.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 8.01
Lightbridge Corporation's selection to participate in the U.S. Department of Energy's Nuclear Energy Launch Pad Program administered by the National Reactor Innovation Center at Idaho National Laboratory represents a material operational and strategic milestone. This government recognition and program participation would be significant to investors evaluating the company's progress in nuclear technology development and commercialization prospects, though the disclosure lacks detail on specific benefits or financial implications.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Soluna announced entry into a co-mining agreement with Bitdeer subsidiary Dory Creek, LLC, deploying approximately 28 MW of Bitcoin mining equipment (1.93 EH/s) at Project Kati 1 in Texas beginning September 2026. This represents a material operational and strategic partnership involving deployment of significant computing infrastructure at Soluna's largest operating site, but does not constitute a traditional M&A transaction, debt issuance, or other specifically-defined event type. The agreement is a material business arrangement affecting Soluna's operational capacity and revenue structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
First Breach announced completion of its first drone prototype flight and provided an update on its strategic manufacturing agreement with Hellbender, Inc. The filing discloses a material operational and product development milestone—successful first flight of a proprietary drone platform—along with manufacturing scaling plans targeting 2,500 drones per week by Q2 2027. This represents a significant strategic expansion beyond the company's core ammunition business into unmanned aerial systems, disclosed via Item 7.01 (Regulation FD Disclosure) with a press release exhibit. While not fitting a specific named category, this is clearly an operational/strategic business event material to investors assessing the company's growth trajectory and diversification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
The filing discloses Advasa Holdings' successful direct listing on the Nasdaq Global Market under ticker "ADBT" on August 25, 2026. While this is a significant capital-raising and market-access event, it does not fit neatly into the standard taxonomy categories. It is not a traditional M&A activity, debt issuance, or dilutive equity issuance (which typically refer to private placements or secondary offerings). A direct listing is a distinct operational and strategic milestone—the company's transition to public markets—that materially affects its capital structure and investor base. This is classified as operational_other because the event is clearly material and operational/strategic in nature, but does not match a specific named category.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-25
Item 8.01
Jazz Pharmaceuticals announced FDA approval of two Ziihera-containing regimens for first-line treatment of HER2+ gastroesophageal adenocarcinoma, representing a significant regulatory and commercial milestone for the company's oncology pipeline. This is a material operational/product event—the approval of a new indication for an existing drug with demonstrated clinical benefit (26.4-month median OS, the longest reported in Phase 3 trials in this setting) that expands the addressable market and establishes a new standard of care. While not a traditional earnings release, M&A, or financial obligation, this regulatory approval materially affects the company's business prospects and product portfolio.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-25
Item 8.01
Spyre announced topline results from the Phase 2 SKYWAY-RA sub-study of SPY072, demonstrating statistically significant efficacy on primary and secondary endpoints with a favorable safety profile. However, the magnitude of effect did not meet the company's internal bar to prioritize advancement of SPY072 as a monotherapy in rheumatoid arthritis, resulting in a strategic decision to deprioritize this development program.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 7.01
The disclosure announces achievement of the first FDA regulatory milestone for CannEpil®—establishment of an Investigational New Animal Drug (INAD) file—under a collaboration agreement with Lupvindol Biosciences. This represents a material operational and strategic development milestone for the Company's veterinary pharmaceutical program, formally initiating FDA regulatory engagement. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the Company's ability to execute its development strategy and advance its new health sciences platform.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 8.01
Zymeworks' partner Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, triggering a $250 million milestone payment to Zymeworks and maintaining eligibility for up to $1.3 billion in additional milestones plus tiered royalties.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 8.01
The FDA has extended the PDUFA target action date for Deramiocel's BLA from August 22, 2026 to November 22, 2026, classifying the submission as a major amendment following submission of 24-month open-label extension data from the Phase 3 HOPE-3 study. This is a material regulatory milestone affecting the timeline for a potential product approval, but does not fit neatly into specific categories like earnings_release, ma_activity, or material_litigation. The event is clearly operational/strategic in nature—a regulatory development in the drug approval process—making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-24
EX-99.1
The press release announces removal of a blockade at Endeavour's Terronera Mine in Mexico and resumption of operations on August 24, 2026. This is an operational event affecting mine production and community relations. While not fitting a specific named category, it is clearly material to investors as it directly impacts the company's ability to generate revenue from one of its three operating mines and signals resolution of a significant operational disruption.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-24
America Great Health discloses results of a preliminary clinical observation study of ion-modified peptide products (AX-3 and PPY-3) conducted at a Chinese hospital from December 2024 through May 2026. The study involved ten subjects with various malignancies and one inflammatory condition, with observations of clinical symptoms, vital signs, and laboratory parameters. While the company explicitly cautions that this was a small, non-randomized, non-blinded, non-placebo-controlled observational study with significant limitations, and that results cannot establish safety or efficacy, the disclosure of clinical research results on the company's lead investigational products is material to investors evaluating the company's pipeline and development prospects. This is an operational/strategic disclosure of research progress rather than a financial event, governance matter, or legal issue.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-24
Item 8.01
The FDA's grant of Fast Track Designation (FTD) to ERAS-0015 for metastatic pancreatic adenocarcinoma is a material regulatory milestone that accelerates the development and review pathway for a key product candidate. While FTD does not guarantee approval, it represents a significant operational and strategic achievement for a clinical-stage biopharmaceutical company, potentially expediting the path to market and supporting the company's planned Phase 3 trial initiation. This is a regulatory/operational event that does not fit the specific categories of earnings, M&A, impairment, or other named types, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 8.01
The FDA placed a clinical hold on RGX-121 following discovery of asymptomatic spine MRI findings in trial participants. The company does not expect to resubmit the BLA in the near term, representing a material regulatory setback to a late-stage gene therapy program.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-24
Item 8.01
The company disclosed supplemental risk factors related to a Commercial Agreement requiring substantial capital investment in data center development and GPU acquisition, highlighting financing risks, construction and operational risks, and regulatory challenges that could impair the company's ability to perform its contractual obligations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-24
EX-99.1
IceCure announced entry into an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. This is a material operational/commercial event—a strategic partnership expanding the company's European commercialization footprint in a key market where the THERMAC clinical trial is advancing to Phase III. While not a discrete M&A transaction, the exclusive distribution agreement represents a significant commercial milestone that would affect investor assessment of the company's market access and revenue potential.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Evolution Metals announced preliminary inclusion in the Russell 3000® and Russell 2000® indexes effective September 21, 2026, disclosed under Item 7.01 (Regulation FD Disclosure). While index inclusion is a capital-markets milestone that could broaden institutional investor visibility and liquidity, it is primarily an operational/strategic recognition event rather than a discrete financial, governance, or existential event. The filing emphasizes the company's expansion of rare earth magnet production capacity and commercial certifications, positioning this as a business milestone. Index inclusion itself does not constitute a material financial obligation, executive change, M&A activity, or accounting event, but would materially affect investor perception of the company's market profile and accessibility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-24
EX-99.1
The press release announces a significant intellectual property milestone: publication of a U.S. patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders through SciSparc's subsidiary NeuroThera's ongoing collaboration with Clearmind Medicine. This represents advancement of the joint IP portfolio (now thirteen published patent applications globally) and occurs amid FDA finalization of guidance on psychedelic drug development explicitly including MDMA. While this is a material operational and strategic development for the company's drug development pipeline, it does not fit neatly into the specific event categories (it is neither a discrete M&A transaction, a regulatory approval, nor a material contract announcement in the traditional sense), making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-24
EX-99.1
This press release announces the U.S. publication of a patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders, resulting from Clearmind's collaboration with NeuroThera Labs. The disclosure highlights intellectual property advancement (13 patent applications generated through the collaboration, now 19 patent families total) and notes the FDA's recent finalization of guidance explicitly including MDMA in its psychedelic drug development framework. While this is a material operational and strategic milestone for a clinical-stage biotech—expanding IP portfolio and regulatory clarity—it does not fit the discrete event categories of earnings release, M&A activity, executive changes, or other specific material events. The patent publication and regulatory context represent a significant operational/strategic development that would affect investor assessment of the company's pipeline and competitive position.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-24
EX-99.1
IsoEnergy has entered into an Exploration Agreement with Kineepik Métis Local Inc. to establish a framework for engagement, information sharing, and collaboration as the company advances uranium exploration in Saskatchewan. This is a material operational and strategic partnership that provides community members with employment, training, and business opportunities. While not a discrete M&A transaction, debt issuance, or other named event type, the agreement represents a significant operational milestone for the company's exploration activities and community relations in a key jurisdiction.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-24
EX-99.2
ZenaDrone commenced in-house PCB flight testing as part of a vertical integration strategy to advance toward NDAA-compliant Blue UAS certification and capture U.S. defense market opportunities. The initiative emphasizes supply-chain resilience and margin improvement while positioning the company for defense contracts.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-24
EX-99.3
ZenaTech expanded its ZenaWorx software to include digital terrain modeling (DTM) capabilities and signed its first paying customer in the AI data center construction market. The expansion represents a new recurring revenue opportunity in the global digital elevation model market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-24
EX-99.4
ZenaTech announced anticipated competitive advantages resulting from a U.S. Presidential Proclamation imposing Section 232 tariffs of up to 100% on imported drones and components, with preferential 15% treatment for Taiwan-sourced products. The tariff policy validates the company's vertical integration strategy and could materially enhance its competitive position in U.S. defense markets.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 7.01
BioCardia announced FDA confirmation of meeting minutes supporting a follow-on De Novo pre-submission for its Helix Transendocardial Delivery Catheter. This is a regulatory milestone—the FDA's acceptance of pre-submission meeting minutes—that advances the company's pathway toward device approval. While not a final approval or a specific operational contract, this represents material progress on a key product platform that the company intends to leverage for commercial partnerships. The event is clearly operational/regulatory in nature but does not fit the specific categories of earnings, M&A, litigation, or other named types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-24
Item 1.01
CPS Technologies entered into a 12-year-10-month lease for 80,000 square feet in Attleboro, Massachusetts, involving relocation of corporate offices, manufacturing, and product development from Norton, Massachusetts. While Item 1.01 typically covers M&A activity, this is a material operational/strategic commitment involving significant capital expenditure ($1.6M+ company investment, $3.2M landlord contribution), long-term financial obligations ($85K-$1.05M+ monthly rent), and a major facility consolidation. The event is material to investors but does not fit the M&A taxonomy; it is best classified as a material operational/strategic event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 8.01
Edible Garden entered into a non-binding memorandum of understanding with Square Roots Urban Growers on August 21, 2026, to co-develop premium RTD beverages using nutrient-dense crops. This is a material strategic partnership involving joint product development, shared manufacturing, and a multi-phase collaboration designed to establish a "farm-to-formula" product line. While the MOU is non-binding, the scope and strategic importance of the partnership—particularly given Edible Garden's stated transformation into higher-margin, shelf-stable nutrition categories—makes this a material operational and strategic event that would affect a reasonable investor's assessment of the company's growth prospects and product diversification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Soluna announced the closing of a 397-acre land purchase in Briscoe County, Texas for "Project Dorothy 3," a planned 300 MW renewable-first AI computing campus. This is a material operational/strategic milestone involving significant capital deployment and real estate acquisition that advances the company's development pipeline (6.3 GW across multiple sites). While not a traditional M&A transaction (acquisition of another company), it represents a material operational event—a major property acquisition and project development milestone—that would affect a reasonable investor's assessment of the company's growth trajectory and capital allocation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-24
The filing discloses Datacentrex's secured colocation capacity and deployment of over 500 additional ElphaPex DG2 Scrypt ASIC miners, expected to increase deployed hashrate by approximately 21%. While filed under Item 2.02 (Results of Operations and Financial Condition), the core disclosure is an operational/strategic business milestone—the expansion of the mining fleet—rather than financial results or earnings. This represents a material operational development for a digital asset mining company, but does not fit the specific categories of M&A activity, debt issuance, or other named financial events.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-24
The filing discloses via Item 7.01 (Regulation FD Disclosure) a press release announcing operational updates on Bitmine's cryptocurrency holdings and treasury strategy, including ETH accumulation progress (5.85 million tokens, 4.8% of total ETH supply), staking operations (MAVAN platform), and total crypto/cash holdings of $14.9 billion. While the disclosure centers on strategic digital asset management and operational milestones rather than a specific named event type (no M&A, earnings release, executive change, or financial restatement), the magnitude of holdings and strategic positioning would materially affect a reasonable investor's assessment of the company's operations and financial condition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
The filing discloses a five-year lease extension with Johns Hopkins University, the company's largest tenant, extending the Baltimore property lease term to December 31, 2031. This is a material operational event involving a key tenant relationship at a significant property, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types. The extension of a major tenant lease is a strategic operational matter affecting the company's revenue stability and property portfolio.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-24
The filing discloses a strategic shift by newly appointed CEO Jolie Kahn outlining FingerMotion's expansion into enterprise AI and modular compute infrastructure in North America, including a recent 9.9% acquisition of Lyken AI Computing Inc. While the letter addresses operational strategy, capital deployment, and leadership changes (CFO Chris Polimeni's appointment), the core disclosure is a material operational and strategic pivot rather than a discrete event fitting the taxonomy's specific categories. The acquisition of a 9.9% stake in Lyken could qualify as ma_activity, but the letter frames it as one element of a broader strategic repositioning, making the overall event primarily operational in nature.
View raw filing on EDGAR →